Program
ATH434
Also written as “ATH434 dose level 1” and “ATH434 dose level 2”.
Its studies are mostly in Multiple System Atrophy, led by Alterity Therapeutics.
Furthest: phase 2, since Oct 22, 20213 company-led studies, 1 open or runningNext primary completion: Jul 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alterity Therapeutics | 31 open or running | phase 2since Oct 22, 2021 | Oct 22, 2021 | Jul 2029phase 2 · NCT07729852 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 22, 2021First study: phase 2 study in Multiple System AtrophyFirst studyNCT05109091 · 77 enrolled · United States, Australia, France and more
- May 9, 2023Phase 2 study in Multiple System AtrophyNCT05864365 · 10 enrolled · United States
- Jul 16, 2026Phase 2 study in Multiple System AtrophyNCT07729852 · 7 planned · France
Ahead
- Jul 2029Primary completion: phase 2 study in Multiple System AtrophyNCT07729852
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07729852Multiple System Atrophy · France | 2 | By invitation | Jul 2029 | 7 |
| NCT05864365Multiple System Atrophy · United States | 2 | Completed | Feb 26, 2025 | 10 |
| NCT05109091Multiple System Atrophy · United States, Australia, France and more | 2 | Completed | Nov 28, 2024 | 77 |
How it is read
Names in the registry
- “ATH434”, 2 entries
- “ATH434 dose level 1”, 1 entry
- “ATH434 dose level 2”, 1 entry
Conditions, from the studies’ own filings
- Multiple System Atrophy, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.